• Handbook of Her2-Targeted Agents in Breast Cancer See large image

    Handbook of Her2-Targeted Agents in Breast Cancer (Paperback) By (author) Ricardo H Alvarez, By (author) Javier Cortes, By (author) Leticia De Mattos-Arruda, By (author) Mary Falzon, By (author) Angelica Fasolo, By (author) Michael Gandy, By (author) Luca Gianni, By (author) Nadia Harbeck, By (author) Martine Piccart, By (author) Stefania Zambelli

    $47.49 - Save $10.88 18% off - RRP $58.37 Free delivery worldwide Available
    Dispatched in 2 business days
    When will my order arrive?
    Add to basket | Add to wishlist |

    DescriptionBreast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.


Other books

Other books in this category
Showing items 1 to 11 of 11

 

Reviews | Bibliographic data
  • Full bibliographic data for Handbook of Her2-Targeted Agents in Breast Cancer

    Title
    Handbook of Her2-Targeted Agents in Breast Cancer
    Authors and contributors
    By (author) Ricardo H Alvarez, By (author) Javier Cortes, By (author) Leticia De Mattos-Arruda, By (author) Mary Falzon, By (author) Angelica Fasolo, By (author) Michael Gandy, By (author) Luca Gianni, By (author) Nadia Harbeck, By (author) Martine Piccart, By (author) Stefania Zambelli
    Physical properties
    Format: Paperback
    Number of pages: 107
    Width: 127 mm
    Height: 201 mm
    Thickness: 8 mm
    Weight: 126 g
    Language
    English
    ISBN
    ISBN 13: 9781907673931
    ISBN 10: 1907673938
    Classifications

    BIC E4L: HEA
    B&T Book Type: NF
    Nielsen BookScan Product Class 3: S6.2
    Ingram Subject Code: PI
    Libri: I-PI
    LC subject heading:
    DC22: 610
    LC subject heading:
    BIC subject category V2: MJCL
    B&T General Subject: 510
    Warengruppen-Systematik des deutschen Buchhandels: 26920
    Abridged Dewey: 616
    LC classification: RC
    B&T Merchandise Category: MED
    LC subject heading:
    BISAC V2.8: MED071000
    LC subject heading:
    BISAC V2.8: MED062000, MED029000
    LC subject heading:
    BISAC V2.8: MED045000
    LC classification: RM121, R729.5.G4, RA427.9
    DC23: 616.99449
    LC classification: R-RZ, RC254-282, RC1-1245
    Thema V1.0: MJCL, MKG, MBPA
    Edition statement
    2013 ed.
    Illustrations note
    13 black & white illustrations, biography
    Publisher
    Springer Healthcare
    Imprint name
    Springer Healthcare
    Publication date
    14 July 2014
    Publication City/Country
    London
    Author Information
    This book has been written by a collection of some of the foremost experts in the breast cancer field. Dr Ricardo Alvarez is an Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr Javier Cortes is Deputy Director of the Breast Cancer Program, Head of the Breast Cancer and Melanoma Group in the Oncology Department of Vall d'Hebron University Hospital. Dr Mary Falzon is Consultant Histo/Cytopathologist and Divisional Clinical Director for University College London Hospitals in London, UK. Michael Gandy is Head of Clinical and Research Services at University College London Advanced Diagnostics in London, UK. Dr Luca Gianni is the Director of the Department of Medical Oncology at the Hospital San Raffaele in Milan, Italy. Professor Nadia Harbeck is Head of the Breast Center at the University of Munich, Germany and heads the Oncological Therapy and Clinical Trials Unit in Obstetrics and Gynecology. Professor Martine Piccart is Professor of Oncology at the Universite Libre de Bruxelles and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium.
    Table of contents
    Introduction and background biology.- HER2 testing.- HER2-positive breast cancer: adjuvant and neoadjuvant therapy.- HER2-positive metastatic breast cancer: first-line treatment.- HER2-positive metastatic breast cancer: second-line treatment.- Emerging targeted agents for HER2-positive breast cancer.